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Abstract: Bone and muscle have been recognized as endocrine organs since they produce and 
secrete “hormone-like factors” that can mutually influence each other and other tissues, giving rise 
to a “bone–muscle crosstalk”. In our study, we made use of myogenic (C2C12 cells) and osteogenic 
(2T3 cells) cell lines to investigate the effects of muscle cell-produced factors on the maturation 
process of osteoblasts. We found that the myogenic medium has inhibitory effects on bone cell 
differentiation and we identified sclerostin as one of the myokines produced by muscle cells. 
Sclerostin is a secreted glycoprotein reportedly expressed by bone/cartilage cells and is considered 
a negative regulator of bone growth due to its role as an antagonist of the Wnt/β-catenin pathway. 
Given the inhibitory role of sclerostin in bone, we analyzed its expression by muscle cells and how 
it affects bone formation and homeostasis. Firstly, we characterized and quantified sclerostin 
synthesis by a myoblast cell line (C2C12) and by murine primary muscle cells by Western blotting, 
real-time PCR, immunofluorescence, and ELISA assay. Next, we investigated in vivo production of 
sclerostin in distinct muscle groups with different metabolic and mechanical loading characteristics. 
This analysis was done in mice of different ages (6 weeks, 5 and 18 months after birth) and revealed 
that sclerostin expression is dynamically modulated in a muscle-specific way during the lifespan. 
Finally, we transiently expressed sclerostin in the hind limb muscles of young mice (2 weeks of age) 
via in vivo electro-transfer of a plasmid containing the SOST gene in order to investigate the effects 
of muscle-specific overproduction of the protein. Our data disclosed an inhibitory role of the 
muscular sclerostin on the bones adjacent to the electroporated muscles. This observation suggests 
that sclerostin released by skeletal muscle might synergistically interact with osseous sclerostin and 
potentiate negative regulation of osteogenesis possibly by acting in a paracrine/local fashion. Our 
data point out a role for muscle as a new source of sclerostin. 
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The musculoskeletal system consists principally of bones, muscles, tendons, 
ligaments, and articular cartilage. These are arranged throughout the body and physically 
and mechanically interact to assure the integrated motor activity and the musculoskeletal 
metabolism/homeostasis [1]. In particular, the musculoskeletal system’s primary function 
includes supporting the body, allowing movement, and protecting vital organs. In this 
system, bones relate to other bones and muscles via connective tissue such as tendons and 
ligaments. Bones provide stability and muscles keep bones in place and allow the motor 
activity. Moreover, the skeletal portion of the system has the role to store calcium and 
phosphorus and contains the hematopoietic system [2]. 
There are several diseases and disorders that may affect this system, and often they 
are very difficult to diagnose due to the close relation of the musculoskeletal system to 
other internal systems. Musculoskeletal conditions range from those that arise in an acute 
manner and are short-lived, such as fractures, to lifelong pathologies associated with 
chronic pain and disability such as genetic diseases (achondroplasia, osteogenesis 
imperfecta, muscular dystrophy, and myopathies) [3,4], metabolic diseases such as 
osteoporosis and osteopenia [5], tumors of the bones and the muscle such as osteosarcoma 
and rhabdomyosarcoma [6], joint diseases such as osteoarthritis and rheumatoid arthritis 
[7], and aging in general characterized by bone and muscle weakness (osteopenia and 
sarcopenia) [8,9]. All these diseases comprise dysregulation of the physiology of all the 
tissues among the musculoskeletal system; therefore, a better understanding of the 
molecular mechanisms responsible for the crosstalk among these tissues is needed. In 
particular, the condition related to musculoskeletal aging is one of the major public health 
interests and is typical of the demographic changes in the population. It is associated with 
a high risk of fractures and joint and muscle hypofunctionality with consequent loss of 
autonomy in elderly people, and this condition is therefore correlated with high morbidity 
and healthcare rates [10,11]. Sarcopenia and osteoporosis are linked and commonly 
associated with aging, often leading to a frailty syndrome, a pathological condition 
characterized by a general decline, which includes multifactorial causes [12,13]. 
During the last decade, bone and muscle were increasingly recognized as interacting 
tissues, not only because of their proximity and their integrated function for motor 
activity, but also for the fact to be recognized as endocrine target tissues and to be 
endocrine organs themselves [14]. In fact, the two tissues interact with each other by 
paracrine and endocrine signals and modulate their mutual development and function 
since intrauterine life to oldness [15]. The muscle–bone crosstalk is supported by 
preclinical and clinical data, showing the presence of many tissue-specific factors released 
by osteoblasts and osteocytes, including prostaglandin E2, osteocalcin, and IGF-1, which 
have a potential impact on skeletal muscle cells. Moreover, a growing number of muscle-
released factors with bone-modulating properties have been identified. These include 
insulin-like growth factor-1 (IGF-1), fibroblast growth factor-2, IL-6, IL-15, myostatin, 
osteoglycin, irisin, and osteoactivin, which have been initially implicated in the 
pathogenesis of sarcopenia but appear to also be regulators of bone remodeling and thus 
potentially relevant for osteoporosis [16–22]. However, despite this recent effort, limited 
data exist about the molecular basis controlling the muscle-to-bone crosstalk. 
In our study, for the first time, we clearly identified a new putative myokine, 
sclerostin, that until recently had been described as a potent inhibitor of bone formation 
produced mainly by osteocytes [23,24]. Our data demonstrate the expression of sclerostin 
both in muscle cells in vitro and in muscles collected from variously aged mice and 
differing in metabolic and load-bearing features. Moreover, through a functional 
approach, we investigated the role of muscle-originated sclerostin in bone formation. In 
conclusion, this study highlights, for the first time, skeletal muscle as a new source of 
sclerostin. Sclerostin produced at the muscular level may act in combination with bone 
sclerostin in severe conditions of increased bone fragility. This discovery is particularly 
relevant for the development of treatments for pathophysiological conditions 
Biomedicines 2021, 9, 71 3 of 24 
 
 
characterized by simultaneous bone and muscle loss, such as aging-associated 
osteoporosis/sarcopenia or forced immobilization. It is of note that this new finding could 
also lead to new paths in the knowledge of the mechanisms underlying genetic diseases 
such as neuromuscular diseases or cancers where both muscle and bone tissues are 
severely affected. Targeting pathways that regulate bone and muscle systemically and/or 
through the manipulation of more localized pathways that facilitate communication 
between the two tissues are the privileged directions for the identification of new 
molecules, which could simultaneously prevent, reduce, or restore bone and muscle age-
related deterioration. 
2. Materials and Methods 
2.1. Cell Cultures 
C2C12 myoblasts (CRL-1772; ATCC) were cultured in a growth medium (GM) 
composed of DMEM containing 10% FBS, 1% penicillin/streptomycin (P/S), and 2 mM L-
glutamine in a 5% CO2 atmosphere at 37 °C. To induce myogenic differentiation, the cells 
were plated on tissue culture plates and grown to 95% confluence before switching to the 
differentiation medium (DM) (DMEM with 5 μg/mL insulin). The cells were replenished 
with fresh DM every 48 h to induce differentiation until 14 days. 
Osteoblastic cell line 2T3 provided by Lynda Bonewald (Indiana University School 
of Medicine, Indianapolis, IN, USA) was cultured in a complete medium composed of a 
MEM supplemented with 10% FBS, 2 mM L-glutamine, and 1% P/S. For osteogenic 
differentiation, a complete medium supplemented with 50 μg/mL ascorbic acid and 4 mM 
β-glycerophosphate was used. The differentiation medium was changed every two days 
of culture. 
C57 primary myoblasts were isolated from limb muscles of young (14–30 days old) 
mice previously injured with a 30-gauge needle and dissociated to isolate pure 
populations of myoblasts as described previously [25]. Primary cultures were plated on 5 
μg/mL laminin-1/collagen-coated dishes and amplified in a growth medium (GM) 
consisting of Ham’s F-12 with 20% FBS, 2.5 ng/mL basic fibroblast growth factor, 2 mM L-
glutamine, and 1% P/S. 
To induce differentiation, myoblast cultures were seeded on coated dishes at 60% 
confluence and the growth medium was switched to a differentiation medium (DM) 
consisting of DMEM with 2% horse serum, L-glutamine, and P/S. The timepoints analyzed 
were days 1, 3, and 6 of differentiation. All tissue culture reagents were from Thermo 
Fisher, Waltham, MA, USA. 
2.2. Animal Procedures 
In vivo experiments of sclerostin characterization took place in the conventional 
animal facility of Bordeaux University (agreement number 063-917 obtained 7 May 2018). 
Eighteen male C57BL/6 mice at the age of 6 weeks (young; n = 6), 5 months (adult; n = 6) 
and 18 months (old; n = 6) were purchased from Janvier Labs (Saint-Berthevin, France). 
Animal housing and caretaking were provided by the animal facility in accordance with 
the national guidelines. All animal procedures were performed in accordance with the 
European Guidelines for Care and Use of Laboratory Animals. 
Mice were kept under a 12 h–12 h light/dark cycle and the temperature was 
controlled. After the first week of adaptation, animals were euthanized by cervical 
dislocation and the following muscles were dissected: Gastrocnemius, Soleus, 
spinotrapezius, and triceps brachii. 
Each selected muscle and its contralateral were withdrawn: one was snap-frozen for 
molecular biology assays and the other was fixed in 4% paraformaldehyde (PFA) for 
histology. 
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2.3. In Vivo Gene Transfer and Electroporation Procedures 
Eight male C57BL/6 mice (Charles River) all belonging to the same progeny were 
housed in the institutional animal facility (Department of Cellular, Computational and 
Integrative Biology (CIBIO), University of Trento, Trento, Italy) and maintained on 
standard chow ad libitum. Three animals (n = 3) were electroporated with the SOST 
vector, three (n = 3)—with the empty vector, and two (n = 2) were non-electroporated 
(CTRs). The pCMV6 expression plasmid (MR222588, Origene, Rockville, MD, USA) 
containing the SOST gene tagged with Myc-DDK was amplified in Escherichia coli. 
Eleven days after birth, mice were anesthetized by inhaled isoflurane and plasmid 
DNA was injected into the tibialis anterior (TA), quadriceps femoris (QF), and 
gastrocnemius (GA) muscles with a 0.3 mL insulin syringe through a 31-gauge needle in 
a constant volume of ~40 μL. Each animal received ~240 γ of plasmid DNA (80 γ/site). A 
pair of stainless steel plates was then applied over the muscle to encompass the injection 
area. In all the cases, the distance between the electrodes was 4–4.5 mm. Current was 
delivered 5 min after DNA injection as a constant current, square wave pulse with a digital 
stimulator (Panlab 3100, Biological Instruments, Harvard Apparatus, U.S.A. The 
characteristics of the electric field applied were 200 V/cm, 20 ms amplitude, 1 Hz, eight 
consecutive pulses. The animals were then kept warm until recovery. 
The electroporations were performed at days 11 and 17 of age; the animals were then 
sacrificed at 25 days of age. At each timepoint, animal sera were collected. 
Shortly after sacrifice, the animals were X-ray scanned using an In-Vivo Xtreme-
Bruker instrument. Animal studies were approved by the institutional Animal Use and 
Welfare Committee and the National Ministry of Health (protocol No. 62/2020-PR, 
granted on the 29/01/2020). 
2.4. Western Blot 
At the scheduled timepoints, the cells were lysed with the lysis buffer (10 mM Tris-
Cl, pH 7.4–7.6, 1% NP-40, 150 mM NaCl, 10% glycerol, 10 mM EDTA, 20 mM NaF, 5 mM 
sodium pyrophosphate, 1 mM Na3VO4, and freshly added protease inhibitor cocktail) at 
4 °C for 20 min. 
Proteins from animal tissues were extracted by addition of the AT buffer sonicated 3 
times for 10 s each and incubated for 4 h (muscle) or 24 h (bone) at 4 °C with agitation. 
Proteins were resolved by SDS-PAGE, then transferred to 0.2 μm nitrocellulose 
membranes and probed with the following specific primary antibodies: sclerostin 
(ABCAM ab63097), tubulin (Sigma Aldrich, St. Louis, MO, USA, T5168), GAPDH (SIGMA 
G9545). Then, the membranes were washed with Tris-buffered saline Tween (TBST) three 
times and incubated with specific HRP-conjugated secondary antibodies. Finally, the 
membranes were treated with enhanced chemiluminescence (ECL) reagents (Bio-Rad, 
Hercules, CA, USA) according to the manufacturer’s instructions. Images were visualized 
using Image LabTM Software (Bio-Rad, Hercules, CA, USA). 
2.5. RNA Extraction and Quantitative Real-Time PCR 
Total RNA was extracted with an RNeasy kit (Qiagen, Hilden, Germany) or TRIzol 
(Thermo Fisher Scientific, Waltham, MA, USA) and quantified by spectrophotometry with 
a NanoDrop 2000 device (Thermo Fisher Scientific, Waltham, MA, USA). Then, 500 ng of 
the total RNA were reverse-transcribed using an iScriptTM cDNA Synthesis Kit (Bio-Rad, 
Hercules, CA, USA). Levels of mRNA were quantitatively determined on a CFX96 
TouchTM Real-Time PCR Detection System using an SsoFast™ EvaGreen Supermix 
according to the manufacturer’s instructions (Bio-Rad, Hercules, CA, USA). PCR primer 
sequences were as follows: Runx2 forward primer 5′-TTAATCCACAAGGACAGA-3′, 
Runx2 reverse primer 3′-GTAAGACTGGTCATAGGA-5′; Wisp2 forward primer 5′-
TGTGACCAGGCAGTGATG-3′, Wisp2 reverse primer 5′-
AGTGACAAGGGCAGAAAGT-3′; Hprt forward primer 5′-
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GGCATTGCTCTCTCAATGACAA-3′, Hprt reverse primer 5′-
ATGTAGGCCATGAGGTCCAC-3′. 
For the “In vivo SOST overexpression” experiment (electroporation procedure), the 
animal tissues (muscles) were probed with sclerostin forward primer 5′-
AACAACCAGACCATGAAC-3′, sclerostin reverse primer 5′-
TACTCGGACACATCTTTG-3′ (to detect the endogenous sclerostin); sclerostin Myc-Tag 
forward primer 5′-CGGAGCTGGAGAACGCCT-3′, sclerostin Myc-Tag reverse primer 5′-
AATCCAGGATATCATTTGCTGCC-3′ (to detect the exogenous Myc-tagged sclerostin); 
Hprt forward primer 5′-TCA GAC CGC TTT TTG CCG CGA-3′, Hprt reverse primer 5′-
ATC GCT AAT CAC GAC GCT GGG AC-3′. 
Relative gene expression values were calculated by applying the 2−∆∆Ct method [26]: 
using this method, we obtained the fold changes in gene expression normalized to the 
internal control gene Hprt. 
2.6. Alizarin Red Staining and Mineralization 
Matrix mineralization was evaluated by Alizarin Red S (ARS) staining. The cells were 
fixed in 4% paraformaldehyde for 20 min at room temperature. Next, the cell layer was 
stained with 40 mM Alizarin S (Sigma Aldrich, St. Louis, MO, USA - A5533) at pH ~ 4.2 
for 5 min under gentle agitation. Cell preparations were washed with PBS to eliminate 
non-specific staining. To assess the Alizarin Red S staining, 10% cetylpyridinium chloride 
was added into each well and the cells were incubated for 20 min. Optical density was 
measured by spectrophotometry at 570 nm. 
2.7. Alkaline Phosphatase (ALP) Assay 
Alkaline phosphatase (ALP) activity was measured with a Alkaline Phosphatase 
Assay Kit (colorimetric) (Abcam). The staining procedures were performed according to 
the manufacturer’s suggested protocols. The ALP activity was assessed using p-
nitrophenol phosphate (pNPP) as the substrate at pH 10.2 by evaluating the optical 
density of the yellow substance at 405 nm using an iMarkTM Microplate reader (Bio-Rad, 
Hercules, CA, USA). 
2.8. Enzyme-Linked Immunosorbent Assay (ELISA) 
Sclerostin levels in blood serum samples, animal tissues, and cell lysates were 
determined with a quantitative sandwich ELISA. Mouse SOST (EM1815, FineTest, 
Wuhan, Hubei, China) ELISA kits were used according to the standard protocols 
provided by the manufacturer. All samples were assayed in duplicate. 
2.9. Immunofluorescence 
C2C12 and C57 cells grown on glass coverslips were fixed in 4% paraformaldehyde 
at 4 °C for 20 min, blocked in 4% (w/v) bovine serum albumin (BSA) PBS and incubated 
with primary anti-sclerostin (ab63097, Abcam, Cambridge, United Kingdom) anti-MyoD 
antibody (Santa Cruz Biotechnology, Dallas, USA) overnight at 4 °C. Coverslips were next 
washed with PBS and incubated with fluorescence-labeled secondary antibodies (Thermo 
Scientific, Waltham, MA, USA) for 1 h at room temperature. Slides were mounted with a 
10% DABCO (1,4-diazabicyclo[2.2.2]octane) solution and were observed using a Nikon 
A1 confocal laser scanning microscope. The confocal serial sections were processed with 
ImageJ software to obtain three-dimensional projections and image rendering was 
performed using Adobe Photoshop CS 8.0 software (Adobe Systems, San Jose, CA, USA). 
All the images shown in this paper are representative of at least 3 independent 
experiments carried out under the same conditions. 
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2.10. Histological Staining and Immunohistochemistry 
Animal tissues (muscle, bone) were fixed with 4% PFA overnight. Next, the samples 
were processed for paraffin embedding (Leica EG1150 H) following the procedure 
described here: 70% ethanol for 30 min, three times in 95% ethanol (1 h each), three times 
in 100% ethanol (1 h each), three times in toluene (1 h each), and two times in paraffin (1 
h each). After paraffin embedding, 5–7 μm sections were obtained from each sample by 
means of a Leica RM2155 microtome (Leica Inc. Wetzlar, Germany). 
Hematoxylin and eosin (H&E) staining was performed on murine muscles and bone 
tissues. Briefly, two slides per muscle were deparaffinized by means of xylene (two times 
for 5 min each), hydrated through a graded series of alcohol (100%, 95%, 80%, and 70%) 
for 5 min each, and rinsed; first with tap water and then with deionized water for 1 min 
each. After the dehydration procedure, the slides were stained with a Carazzi hematoxylin 
solution (C0203, DiaPath, Bergamo, Italy), rinsed with tap water, stained with alcoholic 
0.5% eosin Y (C0353, DiaPath, Bergamo, Italy), and then rinsed with deionized water for 
1 min each. 
Histomorphometric analysis was conducted on the right and left femurs. Briefly, 
both femurs were removed from each animal, deprived of soft tissues, fixed in PBS – 4% 
paraformaldehyde (pH 7.4), dehydrated in graded ethanol, and paraffin-embedded. The 
femurs were cut sagittally at the distal metaphyseal level and transversally cut at the mid-
diaphyseal region to obtain serial 5 μm-thick sections for histomorphometric analysis 
(ImageJ software, 1.52v, NIH). The sections were stained with H&E to measure the 
following static histomorphometric parameters: trabecular bone volume (BV/TV), 
trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp) 
of the distal femoral metaphyses, as well as the cortical bone area (Ct-B-Ar) of femoral 
mid-diaphyses. The areas in which the measurements were performed were selected as 
previously described. 
For immunohistochemistry staining, from the paraffin block of each case, we cut a 4 
μm-thick slides for immunohistochemical analysis against CD34 (pre-diluted QBEnd/10 
Mouse Monoclonal Antibody clone; Ventana Medical Systems, Tucson, AZ, USA) and 
CD45/LCA (pre-diluted 2B11&PD7/26 Mouse Monoclonal Antibody clone; Cell 
Marque™- a Sigma-Aldrich®, St. Louis, MO, USA) using a Bench Mark ULTRA automated 
stainer (Ventana Medical Systems, Tucson, AZ, USA). 
For both antibodies, microwave oven irradiation was used as the 
immunohistochemical antigen unmasking treatment. In addition, a pre-diluted ULTRA 
Cell Conditioning Solution (ULTRA CC1—Ventana) was used as a pre-treatment step in 
the processing of tissue samples for immunohistochemistry reaction. Sample sections of 
the vascular tumor and lymphoid tissue were used as the internal control for CD34 and 
LCA/CD45 markers, respectively. The sections were blocked for non-specific binding with 
3% normal bovine serum and incubated with primary antibodies for 1 h at room 
temperature. For immunofluorescence, the sections were then incubated with secondary 
antibodies at 1:200 for 30 min at room temperature (DABCO). The sections were mounted 
with a VECTASHIELD HardSet mounting medium. All the stained sections were 
evaluated under a Nikon Eclipse Ni microscope (Nikon) equipped with a DS-Fi2 camera 
(Nikon) and processed by means of NIS-Elements D 5.11.00 software (Nikon, Rochester, 
New York, USA). 
2.11. Micro-CT Measurements 
Micro-CT scanning was carried out on both left and right tibiae of C57BL/6 mice after 
electroporation and bone harvesting. Micro-CT scanning and analysis were performed 
using a KEVEX PXS10 130 kV–0.5 mA X-ray tube and a Photonic Science VHR1 CCD 
(charge-coupled device) camera with a fiber optic plate with a scintillator (FOS) 4000 × 
2600 (9 μm pixel). The isometric voxel size was 4.5 μm and the X-ray tube potential was 
70 kV. 
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For each tibia, axial sections (from distal epiphysis to middle diaphysis) were 
acquired and stacked in a single DICOM (Digital Imaging and Communications in 
Medicine) file. The acquisition volume was reconstructed from each DICOM file and the 
coronal sections were then extracted. The most informative (i.e., with less background and 
more signal, that is, imaged bone) coronal section was selected and analyzed together with 
the previous five and the subsequent five for a total of 11 coronal sections per sample. For 
each section, the epiphysis, metaphysis and metaphyseal plate were segmented separately 
and automatically; in each of the 11 sections, the metaphysis was further segmented 
through the subdivision of metaphyseal trabeculae into 16 different types, or classes. To 
this purpose, a Gabor filter bank was used, as it is a well-established approach to analyze 
objects’ thickness and orientation in grey-level images in computer vision applications 
[27]. In the case of our classification, the trabecular thickness can have a value of 2 or 3 
pixels (therefore, it is related to a range of about 10–15 μm), while the angle of trabecular 
inclination with respect to the metaphyseal plate w quantized by multiples of 22.5 
degrees. Thus, the classes of metaphyseal trabeculae were defined by a unique 
combination of trabecular thickness and orientation as follows in Table 1 
Table 1. The classes of metaphyseal trabeculae were defined by a unique combination of 
trabecular thickness (pixels) and orientation defined by angle degrees. 
Trabecular Class Thickness (pixels) Angle (degrees) 
1 2 0.0 
2 3 0.0 
3 2 22.5 
4 3 22.5 
5 2 45.0 
6 3 45.0 
7 2 67.5 
8 3 67.5 
9 2 90.0 
10 3 90.0 
11 2 112.5 
12 3 112.5 
13 2 135.0 
14 3 135.0 
15 2 157.5 
16 3 157.5 
Each trabecular class identified was analyzed separately considering the trabecular 
number, thickness, shape, and area. The statistical analysis was performed pooling the left 
and right tibiae of the same experimental group (untreated (CTR), empty vector-treated 
(EV-ET), and sclerostin vector-treated (SOST-EV)). First, the three groups of tibiae were 
compared to each other in pairs (i.e., CTR against EV-ET, CTR against SOST-ET, and EV-
ET against SOST-ET, separately). Then, for each pair of groups, their individual tibiae 
were compared in pairs by considering all the possible pairs of inter-group comparison in 
order to verify whether what is observed from the comparison between the groups can 
also be valid for the individual tibiae that compose them. As an example, if the CTR group 
is composed of tibiae 1A and 1B and the EV-ET group is composed of tibiae 2A and 2B, 
after pair-comparing the whole groups (CTR vs. EV-ET), the single samples that compose 
them are pair-compared in all possible combinations (1A vs. 2A, 1A vs. 2B, 1B vs. 2A, 1B 
vs. 2B). 
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2.12. Statistical Analyses 
All the data were analyzed using Prism version 6.0e (GraphPad Software, Graph Pad 
Holdings, CA, USA). In vitro data are presented as the means ± standard deviation (SD) 
from three independent experiments. Unless otherwise stated, the data for animal 
experiments are expressed as the means ± standard deviation, and statistical analyses 
were performed using one-way ANOVA followed by Dunnett’s, Sidak, or Tukey’s 
multiple comparison tests. Differences between groups were considered statistically 
significant at p < 0.05. 
3. Results 
3.1. Analysis of the Effects Mediated by Myogenic Medium on Osteoblast Differentiation 
In the first part of this study, we proposed modelling the muscle-to-bone crosstalk 
by differentiating 2T3 osteoblastic cells in a medium conditioned by C2C12 muscle cells. 
Particularly, to investigate the effect of sequential patterns of myokines secreted during 
the process of muscle differentiation, we planned to use media from C2C12 cultures 
maintained in differentiating conditions for different amounts of time. With the goal to 
set the proper conditions for this experiment, we initially characterized the differentiation 
process in both myogenic C2C12 cells and osteogenic 2T3 cells lines. Figure 1A illustrates 
the morphological changes occurring during the in vitro lineage progression of C2C12 
myoblasts. Terminally differentiated myotubes were initially apparent after four days of 
culture and became progressively predominant at later timepoints. The myogenic 
properties of the C2C12 cells were confirmed by the presence of the well-known myogenic 
transcription factor MyoD (Figure 1B). In order to evaluate differentiation of the osteoblast 
cell line 2T3, we performed functional assays, such as the Alizarin Red assay and the 
Alkaline Phosphatase Assay, demonstrating a progressive increase in the mineral matrix 
amount and enzyme activity during the osteogenic maturation process (Figure 1C,D). 




Figure 1. (A) Representative bright-field images of C2C12 cells along the differentiation process. 
D0: cycling cells. D1, D4, D6, D14 are differentiated cells for 1, 4, 6, and 14 days, respectively. (B) 
Immunofluorescence staining of MyoD of C2C12 cycling cells (D0) and differentiated cells (D6). 
Blue color is DAPI staining and Red color is MyoD staining (C,D) Alizarin Red staining (C) and 
ALP assay (D) of 2T3 cells differentiated for the indicated days. Student’s t-test (vs. the sample 
named 0) was applied with p < 0.05 (*) and p < 0.005 (**). 
After having established a protocol for efficient differentiation of C2C12 myoblasts 
and 2T3 osteoblasts, we collected C2C12 culture supernatants at early (1 day of culture in 
differentiating conditions, CM1), mid (6 days of culture, CM6), or late (14 days of culture, 
CM14) stages of differentiation and we tested their effects on osteoblast maturation by 
adding 25% C2C12-conditioned media to the osteogenic differentiation medium along 5 
days of culture (Figure 2A). We set up a control condition by adding a 25% cycling 
myoblast medium to the osteoblast maturation medium (CM0). Alizarin staining revealed 
a significant decrease in mineralization (i.e., maturation) of the osteoblasts differentiated 
with CM1*** compared to the control condition (CM0) (Figure 2B). Furthermore, the CM6 
condition and, at a minor extent, the CM14 condition showed a tendency toward reduced 
mineralization. The ALP activity assay revealed a similar trend showing the CM1 
condition significantly lower than the CM0 controls (Figure 2C). Therefore, our initial 
observations indicate that the factors dynamically secreted by differentiating C2C12 cells 
are able to significantly alter the functional maturation of osteoblasts. 




Figure 2. (A) Graphical scheme of the experimental workflow. A quarter of the medium obtained by C2C12 cells in cycling 
(CM0 used as reference) and in differentiating conditions (CM1–CM7–CM14) was added to three quarters of the 
osteogenic differentiating medium on 2T3 cells. Osteoblast cells were maintained in the differentiation medium for five 
days. (B,C) Alizarin Red staining and ALP assay of differentiated 2T3 cells conditioned with C2C12 media (CM0–CM1–
CM6–CM14). Student’s t-test (vs. sample CM0) was applied with p < 0.05 (*) and p < 0.005 (**) (D,E) Messenger RNA was 
extracted from differentiated 2T3 cells and the relative expression of the osteogenic markers Runx2 and Wisp2 was 
evaluated. Statistical significance was obtained using one-way ANOVA + Dunnett’s post test vs. CM0. 
Next, we attempted to further characterize the impact of the C2C12-conditioned 
media on the 2T3 osteogenic program by performing an RT-PCR analysis of the osteogenic 
genes Runx2 and Wisp2, an endpoint of the Wnt signaling pathway that was recently 
described as a reliable marker of osteogenesis by our group [28]. While we found a 
constant expression of Runx2 during myogenic modulation of the 2T3 osteoblast 
differentiation (Figure 2D), the transcription level of Wisp2 was consistently reduced, 
with statistically significant differences during myogenic conditioning from the CM1 to 
the CM14 setpoint (Figure 2E), corroborating the data obtained through the functional 
Alizarin and ALP assays. 
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3.2. Sclerostin Characterization in Muscle Cell Lines and in Primary Muscle Tissues 
With the goal to get mechanistic insights into the agent putatively responsible for the 
slowdown of osteogenic maturation induced by muscle cells, we pointed our attention to 
negative modulators of bone mineralization that are reportedly able to modify the Wnt 
signaling pathway and therefore may explain the dramatic alteration of Wisp2 expression 
induced by the muscle-conditioned media. Particularly, we hypothesized that a possible 
candidate could be sclerostin. Indeed, sclerostin is a major secreted inhibitor of bone 
formation and stands out as an important actor upstream of the Wnt signaling pathway. 
Sclerostin was generally considered an osteocyte-specific protein, since sclerostin mRNA 
and proteins were detected in mouse and human bones, and the expression was restricted 
to osteocytes [23,24]. Despite circumstantial documentation of the presence of SOST 
transcripts in other organs, including skeletal muscles, little attention has been given so 
far to other tissues as a potential source of sclerostin [29]. 
Therefore, we supposed that it may be involved in the effects shown in the muscle 
cells-conditioned medium during osteogenesis and we decided to investigate for the first 
time the potential synthesis and secretion of sclerostin by muscle cells. Interestingly, we 
found the presence of the sclerostin protein both in C2C12 cells and in the primary 
myoblasts obtained from the muscles of C57 mice. Western blotting revealed that 
sclerostin is readily detectable in cellular extracts of cycling myoblasts and differentiating 
cells (Figure 3A,B). Although differences in intracellular levels of the sclerostin protein 
were not statistically significant between the considered timepoints, these data clearly 
demonstrate the ability of myogenic cells to synthetize the sclerostin protein. The 
expression of sclerostin was also confirmed by immunofluorescence that showed its 
localization in the cytoplasm according to its nature of a secreted glycoprotein (Figure 3C, 
D). Importantly, we also quantified with the ELISA assay the amount of sclerostin released 
by C2C12 and C57 cells into the media (Figure 3E,F). Altogether, this analysis 
demonstrated that sclerostin is expressed by C2C12 and C57 cells at the protein level in 
early, mid, and late stages of differentiation and that it is secreted in the medium in a 
dynamic way during myogenic lineage progression. 
To corroborate our observation of the production of sclerostin by muscle cells in 
vitro, we moved to the in vivo context by analyzing the presence of sclerostin in muscles 
by Western blotting, immunofluorescence, and ELISA techniques. The analysis was 
performed on muscles of mice of different ages (young, 6 weeks; adult, 5 months; old, 18 
months). For each age, muscles with different metabolic profiles were analyzed in parallel. 
Specifically, to observe eventual relations between muscular work and sclerostin 
production, we isolated (i) a muscle predominantly composed of fast or glycolytic fibers 
(gastrocnemius, GA); (ii) a muscle containing a high fraction of slow oxidative fibers 
(soleus, SO), which are subjected to phasic movement and important muscular work; (iii) 
a muscle of the back (trapezius, TR), less loaded according to the phasic activity of the 
limbs. Furthermore, a muscle of the fore limbs (triceps brachii, TB) was isolated to 
compare it with the muscles of the hind limbs (Figure 4A). 





Figure 3. (A,B) C2C12 and C57 maintained in the cycling (DO) and differentiating conditions (D1–D3–D6–D14) were 
analyzed by Western blotting (upper panel). Forty ug of protein extracts were resolved by SDS-PAGE and sclerostin 
expression was revealed. GAPDH/actin or tubulin antibodies were used to normalize the signal intensity for at least three 
independent experiments (lower panel). (C,D) Immunofluorescence analysis of sclerostin in C2C12 and C57 cells in the 
growing (D0) and differentiating conditions (D6). (E,F) Quantitative analysis through ELISA assay of the sclerostin 
secreted in the media produced respectively by C2C12 and C57 cells in the cycling and differentiating conditions. Student’s 
t-test (vs. sample named DM0) was applied with p < 0.005 (**) p < 0.0005 (***). The experiment was repeated in triplicate. 
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First, to ensure proper semi-quantification of sclerostin by Western blotting, we 
decided to verify the specificity of the bands recognized by the sclerostin antibody under 
different experimental conditions. To this aim, we processed different mouse tissues such 
as skin and a number of muscle types and we compared the resulting pattern of bands 
with the pattern obtained with femur extracts homogenized in the normal lysis buffer or 
in a lysis buffer with higher reducing conditions (respectively, 5% and 10% of β-
mercapthoetanol). The Western blot image shown in Figure 4B highlights the presence of 
a “bona fide” specific band clearly visible in the femur protein extracts under higher 
reducing conditions. These results suggest that the sclerostin antibody is suitable for the 
Western blot analysis despite the presence of an additional aspecific band migrating slower 
compared to the specific one, particularly apparent in the tissues homogenized with the 
normal lysis buffer. Next, we employed the Western blot technique to analyze the expression 
of sclerostin in distinct muscles obtained from mice of different ages (Figure 4C). Two animals 
per age group were probed. The results obtained with Western blotting show that sclerostin 
is synthesized by all the muscles analyzed with a specific band at the expected molecular 
weight. The presence of the sclerostin protein in the muscle fiber cytosol was also confirmed 
by immunofluorescence on cryosections of gastrocnemius and tibialis anterior muscles 
(Figure 4D). 
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Figure 4. (A) Graphical scheme of the muscles obtained in mice of different ages. (B) Twenty ug of protein extracts obtained 
in different tissues were analyzed for the expression of sclerostin under normal and higher (5–10% β-mercapthoetanol) 
reducing conditions (upper panel). Ponceau staining for visualization of the equal number of loaded samples is in the 
lower panel. (C) Sclerostin expression in protein extracts obtained in different muscles. For each group of muscles, the 
sclerostin expression analysis was repeated for 2 animals (upper panel). Ponceau staining for visualization of the equal 
amount of loaded samples is represented in the lower panel. (D) Frozen sections of the gastrocnemius muscle were 
subjected to immunofluorescence staining of sclerostin. The cell nuclei were stained with DAPI. Scale: 20 μm. (E,F) ELISA 
assay measuring the sclerostin amount in protein extracts from distinct muscle groups collected in mice of different ages: 
young (6 weeks), adult (5 months), old (18 months). The data are represented as the sclerostin amount related to muscle 
weight (E) and to the total extracted protein (F). * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001 
The results of the Western blot analysis also suggest that sclerostin expression might 
be heterogeneously expressed by different muscle groups. By employing a quantitative 
approach such as the ELISA assay, we confirmed the trend revealed by Western blotting. 
The sclerostin quantification obtained by the ELISA assay after normalization for both 
muscle weight and the total protein content indicates that muscular sclerostin production 
is dynamically modulated with time in a muscle group-specific way (Figure 4E,F). 
3.3. In Vivo Muscle-Specific Overexpression of Sclerostin 
In order to investigate a possible role for the muscle form of sclerostin, we performed 
a gain-of-function experiment. We overexpressed transiently, via electroporation (ET), a 
plasmid containing the SOST gene in muscles of young mice. As detailed in Figure 5A, 
this study was based on 3 experimental groups: control (CTR, 2 mice sacrificed at 25 days 
of age without electroporation); empty vector (EV-ET, 3 mice electroporated with the 
pCMV6 vector) and sclerostin vector (SOST-ET, 3 mice electroporated with the pCMV6 
vector in which the SOST gene was cloned). The electroporation was first performed at 11 
days of age and repeated 6 days later, since the exogenous DNA is stable for nearly 7 days 
[29]. Animals were sacrificed at 25 days of age. The muscles selected were quadriceps 
femoris (QF), gastrocnemius (GA), and tibialis anterior (TA) of both hind limbs, which 
allowed targeting the skeletal segments of femur and tibia with the paracrine secretion of 
sclerostin. 
First, to assess the potential injury induced by electroporation, we performed 
histological analysis of the muscles subjected to the procedure. Clinical symptoms were 
not observed in any of the mice during the observation period of two weeks. At sacrifice, 
the electroporated muscles were stained with hematoxylin and eosin (H&E) and with anti-
CD34 and anti-LCA antibodies (Figure 5B,C). Microscopic examination of H&E-stained 
fibers in SOST-electroporated mice revealed a limited presence of inflammatory infiltrates 
(Figure 5B, black arrows), whereas control samples present fibers correctly arranged with 
subsarcolemmal (i.e., peripheral) nuclei. Moreover, the immunohistochemical localization 
of the human leukocyte common antigen (LCA) (Figure 5C), a major membrane 
glycoprotein restricted to leukocytes, showed a recall of granulocytes. Despite the 
induction of inflammation, newly formed vessels were visible in electroporated mice 
(Figure 5B, white arrows), suggesting a local activation of the regenerative process. 
Indeed, functional vascularization was confirmed by the staining with anti-CD34, 
detecting a transmembrane phosphoglycoprotein expressed almost ubiquitously by 
hematopoietic cells. Electroporated muscles presented positively-stained regions at the 
level of muscle mass and the surrounding connective tissue (Figure 5C). Taken together, 
these data suggest that the electroporation procedure may induce mild inflammatory 
reactions, which are counterbalanced by the onset of regenerative processes. 
Next, we checked the electroporation efficiency. We performed a quantitative reverse 
transcription-PCR (qRT-PCR, Figure 5D,E) analysis to detect both the myc-tagged 
sclerostin mRNAs transcribed from the plasmid containing the exogenous SOST gene and 
the total sclerostin mRNAs, which includes the endogenous and exogenous transcripts. 
The results showed consistently a level of myc-tagged sclerostin transcripts in all the 
muscles electroporated with the plasmid containing the SOST gene compared to the ones 
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injected with the empty vector; this comparison reached statistical significance (p < 0.05) 
in tibialis anterior (TA) muscles. This result was confirmed by the analysis of total 
sclerostin expression, which reached significance (p < 0.01) in GA muscles. 
 
Figure 5. (A) Graphical scheme of the sclerostin overexpression experiment. Mice were randomly assigned to three 
different experimental groups: non-electroporated control (CTR) or electroporated with an empty vector or with the 
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sclerostin vector. At the baseline time (before the first electroporation) and before sacrifice, the serum was collected from 
each animal. (B,C) The photographs show representative histological sections of the tibialis anterior of C57BL/6 mice. 
Magnification 20X. Sections of CTR and SOST-ET (SOST-electroporated) mice stained with H&E. The black arrows indicate 
inflammatory infiltrate B). Sections stained with anti-CD34 and anti-LCA antibodies (C). (D,E) Exogenous myc-tagged 
(D) and total sclerostin (E) expression were evaluated by RT-PCR in tibialis anterior, gastrocnemius, and quadriceps 
femoris muscles electroporated with the SOST plasmid (ET, n = 3) or electroporated with an empty vector (Empty, n = 3, 
except for tibialis anterior, n = 2). Data are expressed as the means with the SEM. For each muscle, statistical analyses were 
performed using an unpaired t-test (two-tailed). * p < 0.05. (F) Serum sclerostin levels evaluated through ELISA and 
calculated as the delta (Δ) amount of sclerostin before the electroporation as a starting level and at the moment of sacrifice. 
Although electroporation was performed on a specific set of hind limb muscles (TA, 
GA, QF) which represent only a limited fraction of the entire body muscle mass, we 
decided that evaluating SOST plasmid electroporation might be sufficient to alter the 
quantity of circulating sclerostin. To this aim, we quantified the presence of sclerostin with 
the ELISA assay in animal sera before the first electroporation as a starting level and at 
the moment of sacrifice (Figure 5D). Although the average physiological concentration of 
circulating sclerostin was higher in the SOST-electroporated animals compared to the EV-
electroporated animals both before electroporation (respectively, 360.7 ± 18.05 pg/mL vs. 
273.3 ± 30.3 pg/mL) and at sacrifice (respectively, 385.5 ± 68.5 pg/mL vs. 320.7 ± 22.3 
pg/mL), probably due to individual variability between experimental animals, the 
average amount of circulating sclerostin appeared not to be significantly altered by the 
electroporation of the SOST-expressing plasmid (Figure 5F). The raw data obtained in 
these experiments are listed in Table S1. 
Taken together, these data confirmed that plasmid electroporation was successful in 
yielding a strong local increase in sclerostin in the targeted muscles but highlight a limited 
influence on the circulating levels of sclerostin. 
3.4. Analysis of SOST Overexpression Effects on the Skeleton 
In order to evaluate potential systemic effects on skeletal growth exerted by the 
transient muscular overexpression of sclerostin, we analyzed the responses at the level of 
SOST-electroporated, EV-electroporated, and control littermate mice using X-ray scans. 
The following parameters were evaluated: (i) skeletal malformations of individual bone 
segments, (ii) changes in bone density, (iii) focal structural alterations of bone segments, 
(iv) alterations of the juxta-osseous soft tissues (calcifications or masses). From the 
radiographic comparison of the skeleton of the CTR group (non-electroporated) and of 
the electroporated groups (EV- or SOST-electroporated), it emerged that no growth 
anomalies were found following the electroporation treatment. Furthermore, we could 
not observe differences, at least at the macroscopic skeletal level, which can be ascribed to 
the electroporation of the vector expressing sclerostin (Figure 6A, representative set of 
radiographic images). 




Figure 6. (A) Representative X-ray scans of the skeleton of each mice group: CTR, EV-ET, SOST-
ET. (B) Sagittal section of the distal third of femur (4× magnification). Exemplificative histological 
sections (5 mm) of femurs of non-electroporated (CTR), empty vector (EV-ET), and SOST-vector 
electroporated animals in which the histomorphometric analyses were performed. (C–E) Mean 
values of histomorphometric parameters expressed as BV/TV (%), Tb.N (n/mm), Tb.Sp (mm) in 
trabecular bone of the three animal groups (transversal section at the mid-diaphyseal level of 
100µM 100µM 100µM 
100µM 100µM 100µM 
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femur) (10X magnification). The white line indicates the areas in which histomorphometric 
evaluations were recorded. (F) transversal section at the mid-diaphyseal level of femur (10X 
magnification). The white line indicates the areas in which histomorphometric evaluations were 
recorded. (G,H) Mean values of histomorphometric parameters expressed as CT_B-Ar (mm2) and 
diaphyseal thickness (mm) in cortical bone of the three animal groups. Values are expressed as the 
means ± SEM. * p < 0.05. 
The absence of a generalized bone phenotype is in keeping with inefficient alteration 
of circulating sclerostin levels exerted by SOST plasmid electroporation (see above). 
Nevertheless, accumulating evidence indicate that myokines may affect adjacent bones 
through paracrine mechanisms, relying on their diffusion across muscle and bone tissues 
[30]. In order to evaluate the microscopic events induced by muscle electroporation on 
adjacent skeletal segments, we performed histological staining of bone sections of femurs 
from EV-electroporated (EV-ET), SOST-electroporated (SOST-ET), and non-
electroporated control (CTR) animal groups (Figure 6B,F). The bone amount was clearly 
lower in SOST-ET with respect to EV-ET and CTR animals. This observation was 
confirmed by the static histomorphometric analysis. The ratio between the trabecular bone 
area (BV) and the total area (TV) (i.e., the trabecular bone volume, BV/TV), the trabecular 
number (Tb.N), and the trabecular separation (Tb.Sp) were recorded from the trabecular 
bone of femur (Figure 6C–E), whereas the cortical bone area (Ct-B-Ar) values and 
diaphyseal thickness were recorded from femur cortical bone (Figure 6G,H). The results 
obtained in trabecular bone of the femur distal metaphysis show that the mean values of 
BV/TV and Tb.N in the SOST-ET group were statistically lower with respect to the EV-ET 
group. Moreover, in the SOST-ET group, the Tb.Sp value was significantly higher than in 
the EV-ET group. Conversely, no statistically significant differences were found in the 
cortical bone area (Ct-B-Ar) and diaphyseal thickness at the femoral mid-diaphyseal level 
among the three groups. Collectively, these data suggest that the muscular overexpression 
of sclerostin induced a loss of trabecular bone, but it did not influence cortical bone 
parameters. These data are in line with the fact that the trabecular bone, compared to the 
cortical bone, has a higher turnover rate and is more metabolically active than the cortical 
bone, thus being more easily influenced [31,32]. 
In order to further investigate the effects of muscle-specific sclerostin overproduction 
in adjacent muscles of growing mice via electroporation of a plasmid containing the SOST 
gene, micro-CT analyses were performed on tibiae, which lie between the TA and 
gastrocnemius (GA) muscles targeted by the electroporation. For each tibia, axial sections 
(from distal epiphysis to middle diaphysis) were acquired and then the coronal sections 
were extracted, on which the analysis of the epiphysis, metaphysis, and the epiphyseal 
plate were performed. Figure 7A shows exemplificative coronal sections. At the regional 
level (i.e., epiphysis, metaphysis, epiphyseal plate, and diaphysis as wholes), no 
macroscopic changes in the trabecular organization were detected either in response to 
the EV electroporation or in response to SOST electroporation. 




Figure 7. (A) Exemplificative μCT scans of the metaphyseal plate for each group of animals: CTR, EV-ET, and SOST-ET. 
Yellow arrows show the trabecular orientation. (B) Heat maps that represent the space occupied by the various classes 
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with a color code. Legend of the major represented trabecular classes. Class 8 (yellow, green) is representative of 
perpendicular trabeculae and Class 14 (red) is representative of parallel trabeculae. (C,D) Variation in median values of 
the trabecular number and trabecular area for trabeculae of class 14 (± median absolute deviation (MAD) of trabeculae for 
classes (typology)). Asterisk (*) indicates significant comparisons, p < 0.05 according to the Wilcoxon–Mann–Whitney test 
with the Bonferroni correction. 
The metaphysis was thus further segmented through the subdivision into 16 different 
classes of metaphyseal trabeculae (see Materials and Methods). A representative false 
color map of the composition of trabecular classes present in tibiae from EV-
electroporated (EV-ET), SOST-electroporated (SOST-ET), and non-electroporated control 
(CTR) animals is shown in Figure 7B and highlights differences between experimental 
groups. Analyses were focused on two types of bone trabeculae differently arranged with 
respect to the metaphyseal growing plate in the longitudinal (class-8, PERP) and parallel 
(class-14, PAR) mode. Compared to the control group, the number of trabeculae of class 8 
(PERP) increased following electroporation with an empty vector (+30%, p = 10−5, p < 
0.0021) and then decreased to the levels comparable to those of the control group 
following electroporation with sclerostin, although not in a significantly manner (data not 
shown). Compared to the control group, the number of trabeculae of class 14 (PAR) 
increased following EV electroporation, albeit without significance (EV-ET compared to 
CTR: +16%, p = 0.040, threshold p < 0.0021), but decreased significantly following SOST 
electroporation (SOST-ET compared to EV-ET: −39%, p = 10−10, threshold p < 0.0014) (Figure 
7C). The percentage of metaphysis occupied by the trabeculae (trabecular area) of class 8 
(PERP) increased significantly (compared to the control group) following electroporation 
with an empty vector (+63%, p = 10−5, p < 0.0021) and further increased following 
electroporation with sclerostin (data not shown). As regards the trabecular area occupied 
by the trabeculae of class 14 (PAR), this parameter decreased significantly in EV-
electroporated animals compared to controls (EV-ET compared to CTR: −83%, p = 10−12, 
threshold p < 0.0021) and further decreased following SOST electroporation, but not 
significantly (SOST-ET compared to EV-ET: −29%, p = 10−4, threshold p < 0.0014) (Figure 
7D). Therefore, micro-CT analyses showed a significant decrease of class 14 trabeculae in 
mice that underwent electroporation of a plasmid containing the SOST gene with respect 
to both the mice electroporated with an empty vector and the controls, inversely to class 
8 trabeculae that showed increased values after treatment. 
4. Discussion 
Since the discovery of myostatin in 1997, the first myokine that has been identified, 
secretome-based analysis of the human myocyte culture medium has revealed over 600 
myokines to date [33–37]. However, the majority of these myokines are still not 
sufficiently characterized and need to be extensively investigated to gain insight into the 
pathogenesis of musculoskeletal diseases. 
In this study, we proposed to model in vitro the muscle-to-bone communication with 
osteogenic (2T3) and myogenic (C2C12) cell lines. We found that the conditioned medium 
from differentiating C2C12 cells significantly altered the functional maturation of 
osteoblasts. Therefore, we hypothesized the presence of muscle cell-secreted factors that 
may exert an inhibitory action on osteogenesis. Recently, our group described an 
osteocyte-produced factor, Wisp2, that is an autocrine/paracrine activator of canonical 
Wnt signaling pathway with a potent role in accelerating the osteogenesis process [28]. 
Since sclerostin, an inhibitor of the Wnt/β-catenin pathway that impairs bone formation, 
has become an attractive therapeutic target for treating osteoporosis, we wondered if this 
molecule could also be produced by muscle cells. Despite being considered an osteocyte-
specific protein, SOST mRNA expression was found in other organs, including skeletal 
muscle [29], but no one had ever characterized its actual synthesis by muscle in detail. 
Thus, we analyzed SOST/sclerostin protein expression in C2C12 and C57 muscle cells and 
its secretion into the culture medium, discovering that it is produced at all these levels. 
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We then focused on the characterization of sclerostin in vivo, highlighting that it is widely 
expressed in young, adult, and old mouse muscles and that its expression undergoes 
changes in muscles with different metabolic profiles. 
In order to determine whether muscular sclerostin was similar to that of osseous 
sclerostin in the ability to modulate bone remodeling, a transient gain-of-function 
experiment was performed via plasmid electroporation in muscles of young mice 
characterized by a growing skeleton. This experiment allowed outlining that muscle-
released sclerostin is able to negatively influence the skeletal system. This hypothesis was 
confirmed by (i) the static histomorphometry performed in the trabecular bone of the 
femur distal metaphysis (see above); (ii) the micro-CT analysis performed on tibiae, which 
revealed that SOST overexpression induced a decrease in the number and extension of 
parallel trabeculae. Diversely, the increased amount of perpendicular trabeculae observed 
in SOST-ET animals has an explanation related to skeletal homeostasis. As regards the 
mechanical meaning of trabecular orientation, it is well established that trabecular 
structures are aligned in an organized manner associated with the direction of load 
distribution so that trabeculae are mainly oriented according to the principal applied 
mechanical load directions [38,39]; in line with this evidence, our results on 
electroporation of the plasmid containing the SOST gene show a significant decrease 
under the effect of muscle-derived sclerostin of bony trabeculae less subjected to 
increasing load during growth (class 14), differently from the trabeculae (class 8) mostly 
subjected to increasing load during growth, on which the effect of growing is likely 
dominant compared to other conditioning factors. Thus, we argue that, particularly in 
dynamic situations (such as in the growing skeleton) and despite sophisticated analyses 
(such as micro-CT), the effect of downregulation on osteogenesis exerted by sclerostin of 
muscular origin can be masked by the effect exerted on the skeleton by the increase in 
body mass during somatic growth. 
Taken together, our data indicate that the action of muscular sclerostin resembles the 
activity of the osseous one. Therefore, muscular sclerostin seems to behave as an 
inhibitory factor for osteogenesis that may act synergistically with bone sclerostin to block 
bone deposition. In suggesting the in vivo role of muscular sclerostin on bone tissue, the 
authors are aware of the need to confirm the role of muscular sclerostin after the end of 
the somatic growth before proposing the validation of this protein as a therapeutic target 
for the treatment of bone processes directly linked to the pathological condition or 
indirectly, due to a muscular weakness, such as the condition of muscular dystrophy, 
neuronal atrophy, or cachexia. In line with this target, further steps will be as follows: (i) 
detailed analyses of the biochemical structure of muscular sclerostin (comparing it with 
the osseous one) and (ii) investigations on the potential of anti-sclerostin compounds to 
also inhibit the muscular form. 
In conclusion, this study highlights for the first time the presence of a new form of 
sclerostin produced at the muscular level that can act in combination with bone sclerostin 
in the phenomena of increased bone fragility. Targeting pathways that centrally regulate 
bone and muscle or pathways that facilitate communication between the two tissues are 
the privileged directions for the identification of new chemical molecules, which could 
prevent, reduce, or restore bone loss. 
Supplementary Materials: The following are available online at www.mdpi.com/2227-
9059/9/1/71/s1, Figure S1: Western Blot C2C12 cells; Figure S2: Western blot C57 cells; Table S1: raw 
data obtained by experimental procedures showed in Figure 5D–F; Figure S3: Semi- quantification 
analysis relative to Figure 4B,C. 
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